Suchergebnisse - "Phthalazines"

PubPharm (3.458)

1

PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan

enthalten in: International journal of clinical oncology | 2024

von Matsumura, N. | Mandai, M.

2

Tabersonine Enhances Olaparib Sensitivity through FHL1-Mediated Epithelial-Mesenchymal Transition in an Ovarian Tumor

enthalten in: Journal of natural products | 2024

von Chen, X. | Yan, Y. | Liu, Y. | +2

3

CRABP2 reduces the sensitivity of Olaparib in ovarian cancer by downregulating Caspase-8 and decreasing the production of reactive oxygen species

enthalten in: Chemico-biological interactions | 2024

von Zeng, S. | Xu, Z. | Liu, Y. | +2

4

Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

enthalten in: Cells | 2024

von Turnham, D. | Mullen, M. | Bullock, N. | +13

5

Patient-Reported Outcomes in OlympiA : A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Ganz, P. | Bandos, H. | Španić, T. | +43

6

Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity

enthalten in: Scientific reports | 2024

von Motonari, T. | Yoshino, Y. | Haruta, M. | +8

7

Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor

enthalten in: Molecular biotechnology | 2024

von Chatterjee, P. | Karn, R. | Emerson, I. | +1

8

Pharmacokinetic drug-drug interaction between olaparib and apixaban : a case report

enthalten in: Cancer chemotherapy and pharmacology | 2024

von Berge, M. | Giraud, J. | De Percin, S. | +3

9

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024

von Lorusso, D. | Mouret-Reynier, M. | Harter, P. | +27

10

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Tan, T. | Sammons, S. | Im, Y. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[346]